Endometrial Cancer Clinical Trial
Official title:
Survivors of Uterine Cancer Empowered By Exercise and Healthy Diet (SUCCEED)
RATIONALE: Participating in a diet and exercise program may improve the quality of life of
overweight and obese patients who are in remission from endometrial cancer.
PURPOSE: This randomized phase I trial is studying an exercise and healthy diet program to
see how well it works compared with standard care in patients in remission from stage I or
stage II endometrial cancer.
PRIMARY OBJECTIVE:
* To reduce morbidity and early mortality in endometrial cancer (EC) survivors through
obesity management.
SECONDARY OBJECTIVES:
- To expand and refine a previous pilot study of a behavioral, lifestyle-change education
intervention for use in overweight and obese patients in remission from endometrial
carcinoma.
- To determine the potential effects and variation of each regimen in these patients.
- To explore potential mediators (self-efficacy, depression) and moderators (body mass
index) of healthful dietary and exercise behaviors.
- To evaluate neuronal response to high-versus-low calorie visual food stimuli under
fasted (hunger) and fed (satiated) states in brain regions of interest (hypothalamus,
lateral orbitofrontal cortex, ventral striatum, insula) using blood oxygenation level
dependent (BOLD) functional magnetic resonance imaging (fMRI) before and after a
lifestyle (diet and exercise counseling) intervention or usual care in obese EC
patients. We will also compare the neuronal responses in obese EC patients to those
from normal weight subjects without cancer being seen at the same gynecologic clinic;
and, explore modification of the neuronal signals by candidate genes and serum
biomarkers in the hypothalamic pituitary-adrenal axis, serotonergic and inflammatory
pathways.
OUTLINE: Patients are stratified according to body mass index (25.0-39.9 vs ≥ 40) and
randomized to 1 of 2 intervention arms.
- Arm I: Patients receive a lifestyle intervention, "Survivors of Uterine Cancer
Empowered by Exercise and Healthy Diet (SUCCEED)", on a group and individual basis
consisting of nutrition, exercise, and behavioral modification counseling from a
physician, psychologist, registered dietitian, and physical therapist. Sixteen group
sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months. Weight and body mass
index, satisfaction with study treatment, and exercise/activity logs are assessed
weekly and biweekly. Patients receive additional feedback and support during the weeks
not met in a group, including newsletters and telephone and e-mail contact.
- Arm II (control): Patients receive usual care informational brochures, but no lifestyle
counseling, related to weight loss, physical activity, and nutrition.
Patients undergo physician counseling sessions at baseline and 3, 6, and 12 months. Patients
are assessed by weight, anthropometric measures, and body mass index; biomarkers; body
composition by dual-energy x-ray absorptiometry/densitometry (DEXA); co-morbidities by the
Charlson co-morbidity score; depression by the Beck Depression Inventory (BDI); eating
patterns by the Three-Factor Eating Inventory (EI); exercise/physical activity by Leisure
Score Index (LSI) and pedometer step count; nutrient intake by 24-hour recall; quality of
life by the Functional Assessment of Cancer Therapy-General (FACT-G) and Short-form Medical
Outcomes (SF-36); and self-efficacy by the Self-Efficacy Questionnaire (SEQ) and the Weight
Efficacy Life-Style (WEL).
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
| Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
| Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
| Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
| Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
| Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
| Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
| Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
| Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
| Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
| Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
| Completed |
NCT02549989 -
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
|
Phase 2 |